Evidence map›Paper›PMID 34596824›Full record

ArticleInternal and emergency medicine2022

Clinical characteristics and tumor markers in ischemic stroke patients with active cancer.

Tomohisa Nezu, Naohisa Hosomi, Hiroyuki Naito, Shiro Aoki, Tsuyoshi Torii, Takashi Kurashige, Tomohito Sugiura, Daisuke Kuzume, Yuko Morimoto, Takeshi Yoshida and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Tomohisa NezuDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. tomonezu@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0003-4877-2336
Naohisa HosomiDepartment of Neurology, Chikamori Hospital, Kochi, Japan.
Hiroyuki NaitoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Shiro AokiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Tsuyoshi ToriiDepartment of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Takashi KurashigeDepartment of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Tomohito SugiuraDepartment of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Daisuke KuzumeDepartment of Neurology, Chikamori Hospital, Kochi, Japan.
Yuko MorimotoDepartment of Neurology, Chikamori Hospital, Kochi, Japan.
Takeshi YoshidaDepartment of Rheumatology, Chikamori Hospital, Kochi, Japan.
Yoshiki YagitaDepartment of Stroke Medicine, Kawasaki Medical School, Okayama, Japan.
Naoki OyamaDepartment of Stroke Medicine, Kawasaki Medical School, Okayama, Japan.
Yuji ShigaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Naoto KinoshitaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Teppei KamimuraDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroki UenoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Tomohiko OhshitaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroshima University · JPChikamori Hospital · JPNational Hospital Organization · JPKawasaki Medical School · JP

Funding

the japan society for the promotion of science kakenhi 17K17907the japan society for the promotion of science kakenhi 20K16579
6 · The paper itself

Abstract

Cancer-associated ischemic stroke (CAS) refers to a hypercoagulation disorder related to malignant tumors, especially adenocarcinoma. Carbohydrate antigen (CA) 125 is a mucinous serum marker that might reflect hypercoagulation status, but the association between CA 125 and CAS is unclear across various types of cancer. The aim of this study was to investigate the associations among tumor markers, coagulation markers, and clinical factors in acute ischemic stroke (AIS) patients with active cancer. Consecutive AIS patients with active cancer (a diagnosis or ongoing active therapy for cancer within 6 months) were prospectively enrolled at four hospitals. D-dimer, C-reactive protein (CRP), carcinoembryonic antigen (CEA), CA19-9, and CA 125 levels were measured. Of 120 AIS patients with active cancer, 47 were diagnosed with CAS. CA 125 had the strongest correlations with D-dimer and CRP (ρ = 0.543, p < 0.001 and ρ = 0.452, p < 0.001, respectively). The areas under the receiver-operating characteristic curves for the diagnosis of CAS were 0.812 (95% CI 0.718-0.878) for CA 125, 0.714 (95% CI 0.602-0.801) for CEA, and 0.663 (95% CI 0.552-0.759) for CA 19-9. Multivariable analysis revealed that CA 125 levels in the highest quartile (OR 2.91, 95% CI 1.68-5.53), multiple lesions in multiple vascular territories observed on diffusion-weighted imaging, the absence of dyslipidemia, and the absence of atrial fibrillation were independently associated with CAS. Increased CA 125 levels, which indicate hypercoagulability, were useful for diagnosing CAS in AIS patients with active cancer.

Indexed as

Ischemic StrokeNeoplasmsStrokeThrombophiliaBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenC-Reactive ProteinHumansBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenC-Reactive ProteinCancer-associated strokeCoagulationD-dimerTumor markers

Identifiers

PMID34596824
OpenAlexW3202779053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.